Karen L Hughes1, Mike Clarke2, Paula R Williamson3. 1. MRC North West Hub for Trials Methodology Research, Department of Health Data Science, University of Liverpool, Block F Waterhouse Building, 1-5 Brownlow Street, Liverpool L69 3GL, United Kingdom. Electronic address: Karen.Hughes@liverpool.ac.uk. 2. Centre for Public Health, Institute of Clinical Sciences, Block B, Queen's University Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, United Kingdom. 3. MRC North West Hub for Trials Methodology Research, Department of Health Data Science, University of Liverpool, Block F Waterhouse Building, 1-5 Brownlow Street, Liverpool L69 3GL, United Kingdom.
Abstract
OBJECTIVE: The aim of our review was to bring together studies that had assessed the uptake of core outcome sets (COS) to explore the level of uptake across different COS and areas of health. STUDY DESIGN AND SETTING: We examined the citations of 337 COS reports to identify studies that had assessed the uptake of a particular COS in randomized controlled trials (RCTs) or systematic reviews (SRs). RESULTS: We identified 24 studies that had assessed uptake in RCTs and two studies that had assessed uptake in SRs. The studies covered a total of 17/337 (5%) COS. Uptake rates reported for RCTs varied from 0% of RCTs (gout) to 82% RCTs (rheumatoid arthritis) measuring the full COS. Studies that assessed uptake of individual core outcomes showed a wide variation in uptake between the outcomes. Suggested barriers to uptake included lack of validated measures, lack of patient and other key stakeholder involvement in COS development, and lack of awareness of the COS. CONCLUSIONS: Few studies have been undertaken to assess the uptake of COS in RCTs and SRs. Further studies are needed to assess whether COS have been implemented across a wider range of disease categories and to explore the barriers and facilitators to COS uptake.
OBJECTIVE: The aim of our review was to bring together studies that had assessed the uptake of core outcome sets (COS) to explore the level of uptake across different COS and areas of health. STUDY DESIGN AND SETTING: We examined the citations of 337 COS reports to identify studies that had assessed the uptake of a particular COS in randomized controlled trials (RCTs) or systematic reviews (SRs). RESULTS: We identified 24 studies that had assessed uptake in RCTs and two studies that had assessed uptake in SRs. The studies covered a total of 17/337 (5%) COS. Uptake rates reported for RCTs varied from 0% of RCTs (gout) to 82% RCTs (rheumatoid arthritis) measuring the full COS. Studies that assessed uptake of individual core outcomes showed a wide variation in uptake between the outcomes. Suggested barriers to uptake included lack of validated measures, lack of patient and other key stakeholder involvement in COS development, and lack of awareness of the COS. CONCLUSIONS: Few studies have been undertaken to assess the uptake of COS in RCTs and SRs. Further studies are needed to assess whether COS have been implemented across a wider range of disease categories and to explore the barriers and facilitators to COS uptake.
Authors: Kerry Dwan; Douglas G Altman; Juan A Arnaiz; Jill Bloom; An-Wen Chan; Eugenia Cronin; Evelyne Decullier; Philippa J Easterbrook; Erik Von Elm; Carrol Gamble; Davina Ghersi; John P A Ioannidis; John Simes; Paula R Williamson Journal: PLoS One Date: 2008-08-28 Impact factor: 3.240
Authors: Elizabeth Gargon; Binu Gurung; Nancy Medley; Doug G Altman; Jane M Blazeby; Mike Clarke; Paula R Williamson Journal: PLoS One Date: 2014-06-16 Impact factor: 3.240
Authors: Elizabeth Gargon; Sarah L Gorst; Nicola L Harman; Valerie Smith; Karen Matvienko-Sikar; Paula R Williamson Journal: PLoS One Date: 2018-12-28 Impact factor: 3.240
Authors: Christopher P Millward; Terri S Armstrong; Heather Barrington; Andrew R Brodbelt; Helen Bulbeck; Anthony Byrne; Linda Dirven; Carrol Gamble; Paul L Grundy; Abdurrahman I Islim; Mohsen Javadpour; Sumirat M Keshwara; Sandhya T Krishna; Conor L Mallucci; Anthony G Marson; Michael W McDermott; Torstein R Meling; Kathy Oliver; Barry Pizer; Puneet Plaha; Matthias Preusser; Thomas Santarius; Nisaharan Srikandarajah; Martin J B Taphoorn; Colin Watts; Michael Weller; Paula R Williamson; Gelareh Zadeh; Amir H Zamanipoor Najafabadi; Michael D Jenkinson Journal: Neuro Oncol Date: 2022-07-01 Impact factor: 13.029
Authors: Bina Ram; Kimberley A Foley; Esther van Sluijs; Dougal S Hargreaves; Russell M Viner; Sonia Saxena Journal: BMJ Open Date: 2022-09-30 Impact factor: 3.006
Authors: Christoffer Bruun Korfitsen; Marie-Louise Kirkegaard Mikkelsen; Anja Ussing; Karen Christina Walker; Jeanett Friis Rohde; Henning Keinke Andersen; Simon Tarp; Mina Nicole Händel Journal: Int J Environ Res Public Health Date: 2022-01-07 Impact factor: 3.390